Adult Ocular Toxocariasis Mimicking Ciliary Body Malignancy

Purpose. To discuss an unusual presentation of ocular toxocariasis. Methods. Case report. Results. A 40-year-old woman presented with decreased vision in the left eye with a long history of recurrent red eye from uveitis. Eosinophilia and positive ELISA titers for Toxocara canis favored the diagnosis of ocular toxocariasis. Over 3 months, an anterior scleral mass had a rapid growth raising the possibility of medulloepithelioma, which rarely can mimic uveitic syndromes. Surgical plan changed from local excision to enucleation. Histopathology demonstrated a large homogeneous mass of chronic inflammatory cells with inflammation of the overlying thinned out sclera, medial rectus insertion, and limbal cornea. The triad of peripheral granuloma, eosinophilia, and positive blood serology established the diagnosis of ocular toxocariasis. Conclusions. Ocular toxocariasis can mimic ocular malignancy such as medulloepithelioma in adults and rarely presents as an anterior scleral mass

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Background: Coronavirus disease 2019 (COVID-19)-related critical illness and acute illness are associated with a risk of venous thromboembolism (VTE).Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected VTE.Methods: ASH formed a multidisciplinary guideline panel and applied strict management strategies to minimize potential bias from conflicts of interest. The panel included 3 patient representatives. The McMaster University GRADE Centre supported the guideline-development process, including performing systematic evidence reviews (up to 19 August 2020). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment.Results: The panel agreed on 2 recommendations. The panel issued conditional recommendations in favor of prophylactic-intensity anticoagulation over intermediate-intensity or therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness or acute illness who do not have confirmed or suspected VTE.Conclusions: These recommendations were based on very low certainty in the evidence, underscoring the need for high-quality, randomized controlled trials comparing different intensities of anticoagulation. They will be updated using a living recommendation approach as new evidence becomes available.Thrombosis and Hemostasi

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients

Background: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE.Methods: ASH formed a multidisciplinary guideline panel that included 3 patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process by performing systematic evidence reviews (up to 5 March 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update on guidelines published in February 2021.Results: The panel agreed on 1 additional recommendation. The panel issued a conditional recommendation in favor of prophylactic-intensity over intermediate-intensity anticoagulation in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE.Conclusions: This recommendation was based on low certainty in the evidence, which underscores the need for additional high-quality, randomized, controlled trials comparing different intensities of anticoagulation in critically ill patients. Other key research priorities include better evidence regarding predictors of thrombosis and bleeding risk in critically ill patients with COVID-19 and the impact of nonanticoagulant therapies (eg, antiviral agents, corticosteroids) on thrombotic risk.Thrombosis and Hemostasi

Measurement of correlated μ−overlineb\mu - {overline b} jet cross sections in ppˉp {\bar p} collisions at s=1.8\sqrt{s}=1.8 TeV

We report on measurements of differential $\mu - {\bar b}$ cross sections, where the muon is from a semi-leptonic $b$ decay and the ${\bar b}$ is identified using precision track reconstruction in jets. The semi-differential correlated cross sections, d$\sigma$/d\Et^{{\bar b}}, d$\sigma$/d\pt^{{\bar b}}, and d$\sigma$/d$\delta\phi(\mu - {\bar b})$ for \pt^{\mu}>~9 GeV/c, $|\eta^{\mu}|$~10 GeV, $|\eta^{{\bar b}}|<$~1.5, are presented and compared to next-to-leading order QCD calculations.Comment: Uses Latex, Article 12 point, figures appended as uuencoded file The full PostScript available via WWW at http://www-cdf.fnal.gov/physics/pub95/cdf3164_mu_bbar_prd_final.p

Measurement of the BB Meson Differential Cross Section, dσ/dpTd\sigma/dp_T, in ppˉp\bar{p} Collisions at s=1.8\sqrt{s} = 1.8 TeV

This paper presents the first direct measurement of the $B$ meson differential cross section, $d\sigma/dp_T$, in $p\bar{p}$ collisions at $\sqrt{s}=1.8$ TeV using a sample of $19.3 \pm 0.7$ pb$^{-1}$ accumulated by the Collider Detector at Fermilab (CDF). The cross section is measured in the central rapidity region $|y| 6.0$ GeV/$c$ by fully reconstructing the $B$ meson decays $B^{+}\to J/\psi K^{+}$ and $B^{0}\to J/\psi K^{*0}(892)$, where $J/\psi \to \mu^+\mu^-$ and $K^{*0} \to K^+ \pi^-$. A comparison is made to the theoretical QCD prediction calculated at next-to-leading order.Comment: 14 pages. Submitted to Phys. Rev. Lett. The postscript file is at http://www-cdf.fnal.gov/physics/pub95/cdf2893_bexcl_xsection.p

Search for New Particles Decaying to Dijets in p-pbar Collisions at sqrt(s)=1.8 TeV

We have used 19 pb**-1 of data collected with the Collider Detector at Fermilab to search for new particles decaying to dijets. We exclude at 95% confidence level models containing the following new particles: axigluons with mass between 200 and 870 GeV, excited quarks with mass between 80 and 570 GeV, and color octet technirhos with mass between 320 and 480 GeV.Comment: Submitted to Physical Review Letters in December 199

The Charge Asymmetry in W-Boson Decays Produced in p-pbar Collisions at sqrt(s) = 1.8 TeV

The charge asymmetry has been measured using $19,039~W$ decays recorded by the CDF detector during the 1992-93 run of the Tevatron Collider. The asymmetry is sensitive to the ratio of $d$ and $u$ quark distributions to $x<0.01$ at $Q^2 \approx M_W^2$, where nonperturbative effects are minimal. It is found that of the two current sets of parton distributions, those of Martin, Roberts and Stirling (MRS) are favored over the sets most recently produced by the CTEQ collaboration. The $W$ asymmetry data provide a stronger constraints on $d/u$ ratio than the recent measurements of $F_2^{\mu n}/F_2^{\mu p}$ which are limited by uncertainties originating from deutron corrections.Comment: to be published in PR

Measurement of σ⋅B(W→eν)\sigma \cdot B (W \to e \nu) and σ⋅B(Z0→e+e−)\sigma \cdot B(Z^0 \to e^+e^-) in ppˉp {\bar p} collisions at s=1.8\sqrt{s}=1.8 TeV

We present a measurement of $\sigma \cdot B(W \to e \nu)$ and $\sigma \cdot B(Z^0 \to e^+e^-)$ in proton - antiproton collisions at $\sqrt{s} =1.8$ TeV using a significantly improved understanding of the integrated luminosity. The data represent an integrated luminosity of 19.7 pb$^{-1}$ from the 1992-1993 run with the Collider Detector at Fermilab (CDF). We find $\sigma \cdot B(W \to e \nu) = 2.49 \pm 0.12$~nb and $\sigma \cdot B(Z^0 \to e^+e^-) = 0.231 \pm 0.012$~nb.Comment: Uses Latex, Article 12 point, figure appended as uuencoded file The full PostScript available via WWW at http://www-cdf.fnal.gov/physics/pub95/cdf3312_sigma_1a_prl_v3.p

Limits on WWZWWZ and WWγWW\gamma couplings from WWWW and WZWZ production in pp‾p\overline{p} collisions at s=1.8\sqrt{s} = 1.8 TeV

Direct limits are set on $WWZ$ and $WW\gamma$ three-boson couplings in a search for $WW$ and $WZ$ production with high transverse momentum in $p\overline{p}$ collisions at $\sqrt{s} = 1.8$ TeV, using the Collider Detector at Fermilab. The results are in agreement with the SU(2) $\times$ U(1) model of electroweak interactions. Assuming Standard Model $WW\gamma$ coupling, the the limits are interpreted as direct evidence for a non-zero $WWZ$ coupling at subprocess energies near 500 GeV. Alternatively, assumiong identical $WWZ$ and $WW\gamma$ couplings, bounds $-0.11 < \kappa < 2.27$ and $-0.81 < \lambda < 0.84$ are obtained at $95\%$ CL for a form factor scale 1000 GeV.Comment: 16 pages, submitted to PRL, URL: http://www-cdf.fnal.gov/physics/pub95/cdf2951_vvprl.p